Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis

Ozgul Muneyyirci-Delale,David F Archer,Charlotte D Owens,Kurt T Barnhart,Linda D Bradley,Eve Feinberg,Veronica Gillispie,Sandra Hurtado,Jin Hee Kim,Alice Wang,Hui Wang,Elizabeth A Stewart

F&S Reports（2021）

引用 10|浏览21

暂无评分

摘要

Elagolix with add-back therapy significantly reduced heavy menstrual bleeding in women with uterine fibroids and coexisting adenomyosis, suggesting that elagolix efficacy was not adversely affected by the presence of adenomyosis (Elaris UF-1 and UF-2 Clinical-Trials.gov numbers, NCT02654054 and NCT02691494).

查看译文

关键词

Adenomyosis,elagolix,uterine fibroids

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要